Fenretinide

N/A

Report date: 2025/04/29 16:58:20
NME

Base Information

Drug NameFenretinide
Drug Alias Namefenretinida芬维A胺fenretinidumLAU-7bHPR +[11] 
ClassificationSmall molecules > Amino acid supplement, Lipids and Vitamins
Mechanisms of ActionApoptosis stimulantsRetinoic acid receptors agonists
TargetsRetinoic acid receptors
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Skin MelanomaCNS Embryonal Tumor +[47] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer InstituteJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesSciTech Development IncThe Ohio State UniversityNational Cancer Institute +[4] 
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)European Institute Of OncologyBarbara Ann Karmanos Cancer Institute +[9] 
Active IndicationsPost-Acute COVID-19 SyndromeAngioimmunoblastic T-cell LymphomaMouth Diseases +[11] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Skin MelanomaCNS Embryonal Tumor +[36] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG